Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil injection for sudden hearing loss
ChiCTR2200064323Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Vasostenoon in acute sensorineural hearing loss (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Hearing tests. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
Vasostenoon
03
Conditions
acute sensorineural hearing loss
Beyond the preview
Go deeper on ChiCTR2200064323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064323.